A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer

Breast Cancer Research and Treatment

Volumn 134, Issue 1, 2012, Pages 13-20

  Rugo, Hope S ^a   Jo Chien, A ^a   Franco, Sandra X ^b   Stopeck, Alison T ^c   Glencer, Alexa ^a   Lahiri, Soumi ^d   Arbushites, Michael C ^d   Scott, Janet ^a   Park, John W ^a   Hudis, Clifford ^e   Nulsen, Ben ^e   Dickler, Maura N ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Memorial Cancer Institute   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d GLAXOSMITHKLINE   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Bevacizumab; Breast cancer; HER2; Lapatinib; Targeted therapy; Tyrosine kinase inhibitor; VEGF

Indexed keywords

BEVACIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB;

ADULT; AGED; ANEMIA; ANOREXIA; BREAST CANCER; CANCER CELL; CLINICAL BENEFIT RATE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIARRHEA; DISEASE MARKER; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DURATION OF RESPONSE; ENDOTHELIUM CELL; EPISTAXIS; FATIGUE; FEMALE; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; GENE OVEREXPRESSION; HEADACHE; HEART LEFT VENTRICLE FAILURE; HUMAN; HYDRONEPHROSIS; HYPERBILIRUBINEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SIDE EFFECT; TIME TO RESPONSE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PROPORTIONAL HAZARDS MODELS; QUINAZOLINES; RECEPTOR, ERBB-2; TREATMENT OUTCOME;

EID: 84863985437     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1918-z     Document Type: Review

References (31)

1. DJ Slamon W Godolphin LA Jones JA Holt SG Wong DE Keith WJ Levin SG Stuart J Udove A Ullrich MF Press 1989 Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 244 707 712 2470152 10.1126/science.2470152 1:STN:280:DyaL1M3kt1Wntg%3D%3D
2. DJ Slamon GM Clark SG Wong WJ Levin A Ullrich WL McGuire 1987 Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 177 182 3798106 10.1126/science.3798106 1:CAS:528:DyaL2sXhtVSht7s%3D
3. EH Romond EA Perez J Bryant VJ Suman CE Geyer Jr NE Davidson E Tan-Chiu S Martino S Paik PA Kaufman SM Swain TM Pisansky L Fehrenbacher LA Kutteh VG Vogel DW Visscher G Yothers RB Jenkins AM Brown SR Dakhil EP Mamounas WL Lingle PM Klein JN Ingle N Wolmark 2005 Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 1673 1684 16236738 10.1056/NEJMoa052122 1:CAS:528:DC%2BD2MXhtFansr3F
4. MJ Piccart-Gebhart M Procter B Leyland-Jones A Goldhirsch M Untch I Smith L Gianni J Baselga R Bell C Jackisch D Cameron M Dowsett CH Barrios G Steger CS Huang M Andersson M Inbar M Lichinitser I Lang U Nitz H Iwata C Thomssen C Lohrisch TM Suter J Ruschoff T Suto V Greatorex C Ward C Straehle E McFadden MS Dolci RD Gelber for the Herceptin Adjuvant (HERA) Trial Study Team 2005 Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 1659 1672 16236737 10.1056/NEJMoa052306 1:CAS:528:DC%2BD2MXhtFansr3L
5. G Valabrega F Montemurro M Aglietta 2007 Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer Ann Oncol 18 977 984 17229773 10.1093/annonc/mdl475 1:STN:280: DC%2BD2szmvF2luw%3D%3D
6. CL Vogel MA Cobleigh D Tripathy JC Gutheil LN Harris L Fehrenbacher DJ Slamon M Murphy WF Novotny M Burchmore S Shak SJ Stewart M Press 2002 Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer J Clin Oncol 20 719 726 11821453 10.1200/JCO.20.3.719 1:CAS:528:DC%2BD38XhsVGmt7o%3D
7. N Ferrara T vis-Smyth 1997 The biology of vascular endothelial growth factor Endocr Rev 18 4 25 9034784 10.1210/er.18.1.4 1:CAS:528:DyaK2sXhsFCiu7s%3D
8. L Yen XL You AE Al Moustafa G Batist NE Hynes S Mader S Meloche MA Alaoui-Jamali 2000 Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis Oncogene 19 3460 3469 10918604 10.1038/sj.onc.1203685 1:CAS:528:DC%2BD3cXlslyhsbs%3D
9. M Epstein R Ayala N Tchekmedyian P Borgstrom M Pegram D Slamon 2002 HER2-overexpressing human breast cancer xenografts exhibit increased angiogenic potential mediated by vascular endothelial growth lactate (VEGF) Breast Cancer Res Treat 76 S143 (Abstract 570)
10. GE Konecny YG Meng M Untch HJ Wang I Bauerfeind M Epstein P Stieber JM Vernes J Gutierrez K Hong M Beryt H Hepp DJ Slamon MD Pegram 2004 Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients Clin Cancer Res 10 1706 1716 15014023 10.1158/1078-0432.CCR-0951-3 1:CAS:528:DC%2BD2cXhvFCltrs%3D
11. SA Hurvitz MD Pegram L-S Lin DS Chan HJ Allen RA Dichmann CT Hagenstad J Barstis RC Hermann EH Hu RL Moroose SP Thomas CL Vogel N Ryba D Elashoff 2009 Final results of a phase II trial evaluating trastuzumab and bevacizumab as first line treatment of HER2-amplified advanced breast cancer Cancer Res 69 854s
12. D Cameron M Casey C Oliva B Newstat B Imwalle CE Geyer 2010 Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial Oncologist 15 924 934 20736298 10.1634/theoncologist.2009-0181 1:CAS:528:DC%2BC3cXhtlWjsbrP
13. D Cameron M Casey M Press D Lindquist T Pienkowski CG Romieu S Chan A Jagiello-Gruszfeld B Kaufman J Crown A Chan M Campone P Viens N Davidson V Gorbounova JI Raats D Skarlos B Newstat D Roychowdhury P Paoletti C Oliva S Rubin S Stein CE Geyer 2008 A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses Breast Cancer Res Treat 112 533 543 18188694 10.1007/s10549-007-9885-0 1:CAS:528:DC%2BD1cXhtl2mu7bI
14. DJ Slamon sM Stemmer S Johnston S Kim M Durante LN Pandite DF Roychowdhury VL Goodman 2009 Phase 2 study of dual VEGF/HER2 blockade with pazopanib + lapatinib in patients with first-line HER2 positive advanced or metastatic (adv/met) breast cancer [abstract] Cancer Res 69 4114 10.1158/0008-5472.SABCS-4114
15. KL Blackwell MD Pegram E Tan-Chiu LS Schwartzberg MC Arbushites JD Maltzman JK Forster SD Rubin SH Stein HJ Burstein 2009 Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens Ann Oncol 20 1026 1031 19179558 10.1093/annonc/mdn759 1:STN:280:DC%2BD1MzmtlGltQ%3D%3D
16. D Slamon HL Gomez FF Kabbinavar O Amit M Richie L Pandite V Goodman 2008 Randomized study of pazopanib + lapatinib vs. lapatinib alone in patients with HER2-positive advanced or metastatic breast cancer [abstract] J Clin Oncol 26 2999 3005 10.1200/JCO.2007.14.0590 (Abstract 1016)
17. M Cristofanilli GT Budd MJ Ellis A Stopeck J Matera MC Miller JM Reuben GV Doyle WJ Allard LW Terstappen DF Hayes 2004 Circulating tumor cells, disease progression, and survival in metastatic breast cancer N Engl J Med 351 781 791 15317891 10.1056/NEJMoa040766 1:CAS:528:DC%2BD2cXntVeitb4%3D
18. JA Garcia JE Rosenberg V Weinberg J Scott M Frohlich JW Park EJ Small 2007 Evaluation and significance of circulating epithelial cells in patients with hormone-refractory prostate cancer BJU Int 99 519 524 17407512 10.1111/j.1464-410X.2007.06659.x
19. P Mancuso A Burlini G Pruneri A Goldhirsch G Martinelli F Bertolini 2001 Resting and activated endothelial cells are increased in the peripheral blood of cancer patients Blood 97 3658 3661 11369666 10.1182/blood.V97.11.3658 1:CAS:528:DC%2BD3MXktFOku7k%3D
20. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein J Verweij GM Van AT van Oosterom MC Christian SG Gwyther 2000 New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 205 216 10655437 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D
21. E Botteri MT Sandri V Bagnardi E Munzone L Zorzino N Rotmensz C Casadio MC Cassatella A Esposito G Curigliano M Salvatici E Verri L Adamoli A Goldhirsch F Nole 2010 Modeling the relationship between circulating tumour cells number and prognosis of metastatic breast cancer Breast Cancer Res Treat 122 211 217 19967556 10.1007/s10549-009-0668-7 1:CAS:528:DC%2BC3cXntlKls74%3D
22. E Munzone F Nolé L Zorzino M Medici I Minchella MC Cassatella C Casadio M Picozzi L Adamoli A Goldhirsch M Sandri 2008 Acquisition of HER-2/neu over-expression on circulating tumor cells (CTCs) in patients (pts) with advanced breast cancer (ABC) during chemotherapy [abstract] J Clin Oncol 26 suppl 11017
23. F Nole E Munzone L Zorzino I Minchella M Salvatici E Botteri M Medici E Verri L Adamoli N Rotmensz A Goldhirsch MT Sandri 2008 Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications Ann Oncol 19 891 897 18056915 10.1093/annonc/mdm558 1:STN:280:DC%2BD1c3nvFSjtw%3D%3D
24. HS Rugo MN Dickler JH Scott DH Moore M Melisko BM Yeh J Caravelli E Brogi C Hudis JW Park 2005 Change in circulating endothelial cells (CEC) and tumor cells (CTC) in patients (pts) receiving bevacizumab and erlotinib for metastatic breast cancer (MBC) predicts stable disease at first evaluation [abstract] J Clin Oncol 23 525 10.1200/JCO.2005.04.192
25. ClinicalTrials.gov Web Site (2011) BETH Study: Treatment of HER2 positive breast cancer with chemotherapy plus trastuzumab vs chemotherapy plus trastuzumab plus bevacizumab. http://www.clinicaltrials.gov/ct2/show/ NCT00625898. Accessed 17 Nov 2011
26. ClinicalTrials.gov Web Site (2011) First-line chemotherapy and trastuzumab with or without bevacizumab in treating patients with metastatic breast cancer that overexpresses HER-2/NEU. http://www.clinicaltrials.gov/ct2/ show/NCT00520975. Accessed Nov 17 2011
27. KL Blackwell EH Kaplan SX Franco PK Marcom JE Maleski MJ Sorensen MS Berger 2004 A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer [abstract] J Clin Oncol 22 3006
28. KL Blackwell HJ Burstein AM Storniolo H Rugo G Sledge M Koehler C Ellis M Casey S Vukelja J Bischoff J Baselga J O'Shaughnessy 2010 Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer J Clin Oncol 28 1124 1130 20124187 10.1200/JCO.2008.21.4437 1:CAS:528:DC%2BC3cXktF2ltLo%3D
29. MA Cobleigh VK Langmuir GW Sledge KD Miller L Haney WF Novotny JD Reimann A Vassel 2003 A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer Semin Oncol 30 117 124 14613032 10.1053/j.seminoncol.2003.08.013 1:CAS:528:DC%2BD3sXhtVSjtrvF
30. J Baselga K Imadalou V Paton D Gray S Swai 2009 Efficacy, safety and tolerability of dual monoclonal antibody therapy with pertuzumab + trastuzumab in HER2+ metastatic breast cancer patients previously treated with trastuzumab [abstract] Cancer Res 69 3138 10.1158/0008-5472.SABCS-3138
31. CL Vogel HA Burris S Limentani R Borson J O'Shaughnessy S Vukelja S Agresta B Klencke M Birkner H Rugo 2009 A phase II study of trastuzumab-DM1 (T-DM1), a HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2 + metastatic breast cancer (MBC): final results [abstract] J Clin Oncol 27 1198 1207 (Abstract 1017)